111.58

0.17% -0.19

After Hours: 111.73 0.15 +0.13%

Biontech Se Adr (BNTX)

Overview News Price History Option Chain Why BNTX Down? Discussions Forecast Dividend History

Biontech Se Adr stock is traded at $111.58, with a volume of 544.99K. It is down -0.17% in the last 24 hours and down -0.62% over the past month. BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.

Previous Close:

$111.77

Open:

$111.58

24h Volume:

544.99K

Relative Volume:

0.59

Market Cap:

$26.53B

Revenue:

$2.91B

Net Income/Loss:

$-544.08M

P/E Ratio:

9.6703

EPS:

11.5384

Net Cash Flow:

$2.51B

1W Performance:

-7.13%

1M Performance:

-0.62%

6M Performance:

+28.53%

1Y Performance:

+22.74%

1-Day Range:

$108.86

$112.01

1-Week Range:

$108.75

$119.86

52-Week Range:

$76.53

$131.49

Biontech Se Adr Stock (BNTX) Company Profile

Name

Biontech Se Adr

Sector

Healthcare (1183)

Industry

Biotechnology (680)

Phone

Address

Employee

6,133

Twitter

@BioNTech_Group

Next Earnings Date

2024-11-04

Latest SEC Filings

BNTX's Discussions on Twitter

Biontech Se Adr Stock (BNTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-24-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-17-24	Upgrade	Jefferies	Hold → Buy
Sep-16-24	Upgrade	JP Morgan	Underweight → Neutral
Aug-07-24	Upgrade	Deutsche Bank	Hold → Buy
Aug-02-24	Upgrade	HSBC Securities	Hold → Buy
May-14-24	Initiated	Evercore ISI	In-line
Feb-23-24	Initiated	BMO Capital Markets	Outperform
Jan-05-24	Initiated	Oppenheimer	Perform
Dec-01-23	Downgrade	JP Morgan	Neutral → Underweight
Oct-16-23	Downgrade	HSBC Securities	Buy → Hold
Jul-14-23	Initiated	HSBC Securities	Buy
May-17-23	Upgrade	Redburn	Neutral → Buy
Dec-15-22	Upgrade	BofA Securities	Neutral → Buy
Aug-17-22	Initiated	Cowen	Market Perform
Jul-13-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jul-06-22	Resumed	Canaccord Genuity	Buy
Feb-01-22	Upgrade	Redburn	Sell → Neutral
Dec-16-21	Initiated	Morgan Stanley	Equal-Weight
Nov-10-21	Upgrade	H.C. Wainwright	Neutral → Buy
Oct-22-21	Initiated	Deutsche Bank	Hold
Oct-07-21	Initiated	Jefferies	Hold
Aug-11-21	Upgrade	Bryan Garnier	Neutral → Buy
Jul-19-21	Resumed	Wolfe Research	Outperform
Jun-16-21	Downgrade	Redburn	Neutral → Sell
May-18-21	Initiated	Goldman	Neutral
May-11-21	Downgrade	Bryan Garnier	Buy → Neutral
Dec-01-20	Downgrade	BofA Securities	Buy → Neutral
Aug-03-20	Resumed	Berenberg	Buy
Jul-21-20	Upgrade	BofA Securities	Neutral → Buy
Jun-30-20	Downgrade	H.C. Wainwright	Buy → Neutral
May-19-20	Upgrade	H.C. Wainwright	Neutral → Buy
Apr-28-20	Downgrade	BofA/Merrill	Buy → Neutral
Mar-18-20	Downgrade	JP Morgan	Overweight → Neutral
Mar-09-20	Initiated	H.C. Wainwright	Neutral
Jan-24-20	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jan-22-20	Downgrade	UBS	Buy → Neutral
Nov-05-19	Initiated	Wolfe Research	Outperform
Nov-04-19	Initiated	Berenberg	Buy
Nov-04-19	Initiated	BofA/Merrill	Buy
Nov-04-19	Initiated	Canaccord Genuity	Buy
Nov-04-19	Initiated	JP Morgan	Overweight
Nov-04-19	Initiated	SVB Leerink	Outperform
Nov-04-19	Initiated	UBS	Buy

View All

Biontech Se Adr Stock (BNTX) Latest News

Oct 21, 2024

BioNTech SE ADR outperforms market despite losses on the day - MarketWatch

Oct 21, 2024

BioNTech's mRNA Technology and Acquired Oncology Programs Could Support a Future Moat - Morningstar

Oct 21, 2024

Oct 18, 2024

A better buy-in window may exist right now for BioNTech SE ADR (BNTX) - SETE News

Oct 15, 2024

Oct 14, 2024

BioNTech SE ADR falls Monday, underperforms market - MarketWatch

Oct 14, 2024

mRNA Cancer Vaccines and Therapeutics Research Report 2024 with Long-term Forecasts to 2028 and 2033: Personalized Medicine and Multivalent mRNA Vaccines Lead the Way - GlobeNewswire Inc.

Oct 14, 2024

Oct 11, 2024

BioNTech SE ADR rises Friday, outperforms market - MarketWatch

Oct 11, 2024

Oct 10, 2024

BioNTech SE ADR rises Thursday, outperforms market - MarketWatch

Oct 10, 2024

Oct 09, 2024

BioNTech SE ADR falls Wednesday, underperforms market - MarketWatch

Oct 09, 2024

Insider’s View: Deciphering BioNTech SE ADR (BNTX)’s Financial Health Through Ratios - The Dwinnex

Oct 09, 2024

Oct 08, 2024